1 / 17

Tamoxifen, Raloxifene , and Exemestane in the Chemoprevention of Breast Cancer

Tamoxifen, Raloxifene , and Exemestane in the Chemoprevention of Breast Cancer. By: Erin Hutzell. Background: Breast Cancer. Second leading cause of death due to cancer among women in 2007 1 in 3 women diagnosed with cancer is diagnosed with breast cancer Risk Factors Environmental

seth
Télécharger la présentation

Tamoxifen, Raloxifene , and Exemestane in the Chemoprevention of Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tamoxifen, Raloxifene, and Exemestane in the Chemoprevention of Breast Cancer By: Erin Hutzell

  2. Background: Breast Cancer • Second leading cause of death due to cancer among women in 2007 • 1 in 3 women diagnosed with cancer is diagnosed with breast cancer • Risk Factors • Environmental • Genetic

  3. Background: Breast Cancer • Invasive VS. Noninvasive • Estrogen Receptor (ER) positive VS. Estrogen Receptor negative • Mechanism causing breast cancer

  4. Background: Chemoprevention and Drugs • Chemoprevention • What is it? • Tamoxifen • Selective Estrogen Receptor Modulator (SERM) • Raloxifene • SERM • Exemestane • Aromatase Inhibitor (AI)

  5. Questions • How effective is each drug in preventing breast cancer? • What are the side-effects of each drug treatment? • Which drug is the best possible chemopreventative measure for breast cancer?

  6. Tamoxifen * Modified from Grese et al 1997

  7. Tamoxifen • NSABP P-1 Study by Fisher et al (1998) • Subject Criteria • 60 years + • 35-59 years with predicted breast cancer risk • History of lobular carcinoma in situ or atypical hyperplasia • Methods • Control group • Tamoxifen group

  8. Tamoxifen • Supported By: • IBIS-I Study (Cuzick et al 2002) • Meta-analysis by Cuzick et al • Not Supported By: • Royal Marsden (Powles et al 1998) • Italian Tamoxifen Prevention Study (Veronesi et al 1998) * Kramer et al. 2004 Top: Fisher et al. 1998 Bottom: Fisher et al. 2005

  9. Tamoxifen • NSABP P-1 (Fisher et al 1998 and 2005) • Osteoporotic Fractures: REDUCED • Invasive Endometrial Cancer: RISK INCREASED • Supported by IBIS-I (Cuzick et al 2002) and Royal Marsden (Powles et al 1998) • Thromboembolic Events: RISK INCREASED • Supported by IBIS-I, Royal Marsden, and Italian Tamoxifen Prevention Study (Veronesi et al 1998) • Conclusion: Tamoxifen is an effective drug but has adverse side-effects * Kramer et al. 2004

  10. Exemestane http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60198

  11. Exemestane • Mammary Prevention.3 (MAP3) Trial by Goss et al (2011) • Subject Criteria • Postmenopausal Women • At least one risk factor • Methods • Exemestane • Placebo

  12. Exemestane • Conclusion: Exemestane is a more effective chemopreventative than Tamoxifen • Supported by: • Intergroup Exemestane Study by Bliss et al (2012) • Exemestane produced better disease-free survival * Goss et al 2011 Comparison of the risk reductions for Tamoxifen and Exemestane Table modified from Zhang et al. 2012

  13. Exemestane Comparison of the side-effects of Tamoxifen, Raloxifene, and Exemestane Table modified from Zhang et al. 2012

  14. Conclusion • Exemestane has the potential to be the best possible chemopreventative measure for breast cancer • Future: • Research Exemestane • Explore Medication Combinations • Demographics of Patients

  15. Bibliography

  16. Bibliography

  17. Questions?

More Related